| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41e7550911d3e588caa3fbc6a252ad80 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cf10b65fce767b499ba942559801d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6b2042eac46e7bd1d468652f801eaa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16e3bc1792ebc2a262124387a4ac7477
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a79e3e1bde9e196b30f4bf67601c5f4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b244d5e5135e7e3b8e660fc8e8cb0066 |
| publicationDate |
2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019153446-A1 |
| titleOfInvention |
Mir-149-3p and method for treating metabolic disease using the same |
| abstract |
MicroRNA, including one of or a combination of the following components: (a) a pri-miRNA of miR-149-3p; (b) a pre-miRNA of miR-149-3p; (c) a mature miRNA of miR-149-3p; (d) a miR-149-3p derivative; (e) a 18-26 nucleotides miRNA having a sequence of 5′-AGGGAGG-3′; and (f) a derivative of the 18-26 nucleotides miRNA of (e). Also provided is a method for treating a metabolic disease. The method includes employing a DNA sequence encoding miR-149-3p as a target gene, constructing an overexpression vector of the miR-149-3p, preparing a pharmaceutical composition including the overexpression vector of the miR-149-3p, and administering the pharmaceutical composition to a patient in need thereof. |
| priorityDate |
2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |